Sammenheng mellom hypersomnolens og COVID-19-pandemien: Den internasjonale COVID-19-søvnstudien (ICOSS)
Forskere fra 15 land inkludert Norge har i denne studien undersøkt hypersomnolens og dagtretthet i forbindelse med COVID-19 restriksjoner som påvirket daglige liv, søvn og døgnrytmer. Totalt svarte 18.785 personer på spørreskjema om blant annet overdreven søvnighet på dagtid og overdreven mengde søvn fra mai til september i 2020. Resultatene viste en stor økning av søvnighet på dagtid, overdreven mengde søvn og fatigue på grunn av COVID-19-pandemien, og man fant dette spesielt blant de med selvrapporterte smitte av COVID-19.
Publisert 08.06.2023
Sist oppdatert 01.11.2024
Tomi Sarkanen, Markku Partinen, Bjørn Bjorvatn, Ilona Merikanto, Christian Benedict, Michael R Nadorff, Courtney J Bolstad, Colin Espie, Kentaro Matsui, Frances Chung, Charles M Morin, Yun Kwok Wing, Thomas Penzel, Tainá Macêdo, Sérgio Mota-Rolim, Brigitte Holzinger, Giuseppe Plazzi, Luigi De Gennaro, Anne-Marie Landtblom, Yuichi Inoue, Mariuz Sieminski, Damien Leger, Yves Dauvilliers
Studien er publisert i Sleep Medicine
Background: The COVID-19 pandemic and related restriction measures have affected our daily life, sleep, and circadian rhythms worldwide. Their effects on hypersomnolence and fatigue remain unclear.
Methods: The International COVID-19 Sleep Study questionnaire which included items on hypersomnolence such as excessive daytime sleepiness (EDS), and excessive quantity of sleep (EQS), as well as sociodemographic factors, sleep patterns, psychological symptoms, and quality of life was distributed in 15 countries across the world from May to September in 2020.
Results: Altogether responses from 18,785 survey participants (65% women, median age 39 years) were available for analysis. Only 2.8% reported having had COVID-19. Compared to before the pandemic, the prevalence of EDS, EQS, and fatigue increased from 17.9% to 25.5%, 1.6%-4.9%, and 19.4%-28.3% amid the pandemic, respectively. In univariate logistic regression models, reports of having a COVID-19 were associated with EQS (OR 5.3; 95%-CI 3.6-8.0), EDS (2.6; 2.0-3.4), and fatigue (2.8; 2.1-3.6). In adjusted multivariate logistic regression, sleep duration shorter than desired (3.9; 3.2-4.7), depressive symptoms (3.1; 2.7-3.5), use of hypnotics (2.3; 1.9-2.8), and having reported COVID-19 (1.9; 1.3-2.6) remained strong predictors of EDS. Similar associations emerged for fatigue. In the multivariate model, depressive symptoms (4.1; 3.6-4.6) and reports of having COVID-19 (2.0; 1.4-2.8) remained associated with EQS.
Conclusions: A large increase in EDS, EQS, and fatigue occurred due to the COVID-19 pandemic, and especially in self-reported cases of COVID-19. These findings warrant a thorough understanding of their pathophysiology to target prevention and treatment strategies for long COVID condition.